Science behind the Study: CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease
This editorial describes the science behind a study of axatilimab to treat chronic graft-versus-host disease.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Patients with HHT received pomalidomide or placebo for 24 weeks. Pomalidomide reduced epistaxis frequency and severity.
The New England Journal of Medicine: Search Results in...
Targeting CSF1R in Chronic GVHD — Lessons in Translation
Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise...
Bending the Overdose Curve — Still Not Enough
The multiple waves of overdose deaths in the United States continue to morph in new and unexpected directions, now driven by fentanyl used in...
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
